文献速递眼底病与葡萄膜炎

玻璃体腔注射雷珠单抗、阿柏西普与贝伐珠单抗治疗视网膜中央静脉阻塞继发黄斑水肿的临床有效性:一项随机临床试验

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2019-01-01

LEAVO研究为前瞻性、三臂、双盲、随机非劣效性试验,在英国44个国民健康服务体系眼科部门纳入463例视网膜中央静脉阻塞继发黄斑水肿患者,随机接受雷珠单抗、阿柏西普或贝伐珠单抗治疗100周。阿柏西普在视力平均变化上非劣效于雷珠单抗,贝伐珠单抗未能确认非劣效于雷珠单抗,阿柏西普组平均注射次数少于雷珠单抗组。

要点

  • 100周时平均最佳矫正视力字母评分增益:雷珠单抗12.5、阿柏西普15.1、贝伐珠单抗9.8。
  • 阿柏西普非劣效于雷珠单抗,意向治疗调整后平均差异2.23个字母(95%CI -2.17至6.63,P<.001)。
  • 贝伐珠单抗未达非劣效于雷珠单抗,调整后平均差异-1.73个字母(95%CI -6.12至2.67,P=.07)。

核心结论

  • 视网膜中央静脉阻塞继发黄斑水肿治疗后,阿柏西普相比雷珠单抗的视力平均变化不更差。
  • 贝伐珠单抗相比雷珠单抗的视力结局不确定,即平均而言视力较基线变化可能更差也可能不更差。

研究设计与样本

  • 前瞻性、三臂、双盲、随机非劣效性试验(LEAVO研究),2014年12月12日至2016年12月16日在英国44个国民健康服务体系眼科部门开展。
  • 纳入标准包括年龄18岁及以上、视网膜中央静脉阻塞继发黄斑水肿导致视力损害不足12个月、研究眼最佳矫正视力早期治疗糖尿病视网膜病变研究字母评分在19(约20/400)至78(约20/32)之间、谱域光学相干断层扫描中心亚区厚度320 μm或以上。
  • 463例参与者按1:1:1随机接受雷珠单抗0.5 mg/0.05 mL(n=155)、阿柏西普2.0 mg/0.05 mL(n=154)或贝伐珠单抗1.25 mg/0.05 mL(n=154)反复玻璃体腔注射治疗100周。
  • 265例(57.2%)为男性,平均(SD)年龄69.1(13.0)岁。
  • 数据分析时间为2019年3月4日至2019年4月26日。

主要发现

  • 100周时平均(SD)最佳矫正视力字母评分增益:雷珠单抗组12.5(21.1)、阿柏西普组15.1(18.7)、贝伐珠单抗组9.8(21.4)。
  • 阿柏西普非劣效于雷珠单抗:意向治疗调整后平均最佳矫正视力差异2.23个字母(95%CI -2.17至6.63,P<.001)。
  • 贝伐珠单抗未达非劣效于雷珠单抗:意向治疗调整后平均最佳矫正视力差异-1.73个字母(95%CI -6.12至2.67,P=.07)。
  • 符合方案分析结论与意向治疗分析相似。
  • 阿柏西普组平均注射次数10.0次,少于雷珠单抗组11.8次(100周时平均差异-1.9,95%CI -2.9至-0.8)。

关键数值与推荐

  • 非劣效性判定标准:意向治疗分析和符合方案分析两者95%CI下限均高于-5个字母。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The comparative clinical effectiveness of ranibizumab, aflibercept, and bevacizumab for the management of macular edema due to central retinal vein occlusion (CRVO) is unclear. OBJECTIVE: To determine whether intravitreal aflibercept or bevacizumab compared with ranibizumab results in a noninferior mean change in vision at 100 weeks for eyes with CRVO-related macular edema. DESIGN, SETTING, AND PARTICIPANTS: This prospective, 3-arm, double-masked, randomized noninferiority trial (Lucentis, Eylea, Avastin in Vein Occlusion [LEAVO] Study) took place from December 12, 2014, through December 16, 2016, at 44 UK National Health Service ophthalmology departments. Inclusion criteria included age 18 years or older, visual impairment due to CRVO-related macular edema of less than 12 months with best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study letter score (approximate Snellen equivalent) in the study eye between 19 (20/400) and 78 (20/32), and spectral domain optical coherence tomography imaging central subfield thickness of 320 μm or greater. Data were analyzed from March 4, 2019, to April 26, 2019. INTERVENTIONS: Participants were randomized (1:1:1) to receive repeated intravitreal injections of ranibizumab (0.5 mg/0.05 mL) (n = 155), aflibercept (2.0 mg/0.05 mL) (n = 154), or bevacizumab (1.25 mg/0.05 mL) (n = 154) for 100 weeks. MAIN OUTCOMES AND MEASURES: Adjusted mean change in BCVA in the study eye at 100 weeks wherein noninferiority was concluded if the lower bounds of the 95% CI of both the intention-to-treat and the per protocol analyses were above -5 letters. RESULTS: Of 463 participants, 265 (57.2%) were male, with a mean (SD) age of 69.1 (13.0) years. The mean (SD) gain in BCVA letter score was 12.5 (21.1) for ranibizumab, 15.1 (18.7) for aflibercept, and 9.8 (21.4) for bevacizumab at 100 weeks. Aflibercept was noninferior to ranibizumab (intention-to-treat-adjusted mean BCVA difference, 2.23 letters; 95% CI, -2.17 to 6.63 letters; P < .001). Bevacizumab was not noninferior to ranibizumab (intention-to-treat-adjusted mean BCVA difference, -1.73 letters; 95% CI, -6.12 to 2.67 letters; P = .07). The per protocol analysis conclusions were similar. Fewer mean injections were given in the aflibercept group (10.0) than in the ranibizumab (11.8) group (mean difference at 100 weeks, -1.9; 95% CI, -2.9 to -0.8). CONCLUSIONS AND RELEVANCE: Mean changes in vision after treatment of macular edema due to CRVO were no worse using aflibercept compared with ranibizumab. Mean changes in vision using bevacizumab compared with ranibizumab were inconclusive regarding vision outcomes (ie, the change in visual acuity from baseline, on average, may be worse or may not be worse when using bevacizumab compared with ranibizumab). TRIAL REGISTRATION: ISRCTN13623634.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hykin P, Prevost AT, Vasconcelos JC, et al. Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial. JAMA Ophthalmol. 2019. PMID: 31465100. doi:10.1001/jamaophthalmol.2019.3305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。